2. Natera Inc. (NASDAQ:NTRA)
Natera, Inc. (NASDAQ: NTRA) takes second place as the strongest combination of rapid growth, commercial scale and improving financial performance in genomic diagnostics.
The company uses genetic sequencing, proprietary algorithms and large clinical datasets across oncology, women’s health and organ health.
Its Signatera product is a personalized blood test designed to detect molecular residual disease. It looks for small amounts of tumor DNA that may remain in a patient’s bloodstream after treatment, allowing doctors to monitor whether cancer could be returning before it becomes visible through conventional imaging.
Second-quarter 2026 revenue increased approximately 38% to $752.8 million. Oncology volume reached roughly 238,000 tests as demand for Signatera continued to accelerate.
The company added around 34,000 new Signatera patients during the quarter and reported record molecular residual disease testing volume. It also benefited from growth in its women’s health and organ health businesses.
Management raised its full-year revenue forecast to between $2.85 billion and $2.91 billion. The company also expected to generate positive cash flow during 2026, an important milestone for a business that has invested aggressively in growth.
Natera, Inc. (NASDAQ: NTRA) ranks above several more obvious pure-play AI companies because its algorithms are connected to products already generating billions of dollars in annualized revenue. This is practical artificial intelligence being used within commercially validated diagnostic services.
Its growing clinical-data library may also create a reinforcing advantage. More tests can produce more data, and more data can support additional clinical studies, improved algorithms and stronger evidence for insurance reimbursement.
The risks include continued GAAP losses, premium valuation and dependence on reimbursement decisions. Genetic-testing companies must also maintain high levels of clinical accuracy because regulatory, legal or quality-control problems can quickly damage physician confidence.
Despite those concerns, Natera, Inc. (NASDAQ: NTRA) offers one of the most compelling growth profiles among Nasdaq-listed healthcare AI stocks. It narrowly misses the top position only because artificial intelligence is less visibly central to its corporate identity than it is for the No. 1 company.
